[legzzalot]

So my friend in PA (who just moved back a few weeks ago) has been having some MS like issues but the doctors can't pinpoint it. He was given an appointment with an MS specialist that thinks he would be a great candidate for a study involving a new drug only given twice a year.

He has no idea what it is and promises to call me tomorrow after he meets the doc. I have never heard of a twice a year therapy....and where do I sign up??? Anyone know what this is?

[NurseNancy]

i don't. but if i was your friend i'd be skeptical and wary of the first course of tx to be in a study.

i hope he does a lot of research first and gets another opinion.

[Kitty]

I googled it........here it is..........

http://abclocal.go.com/wjrt/story?se...lth&id=5952475

[Lady]

Kitty the liink wouldn't open for me.

I tried to get into this trial when it first started and was denied. *sigh*.

biomsmedical.com (I can't post links yet. Not until 10 posts it said.)

It is a 5 minute infusion, done twice a year. MBP8298 which now has been named Dirucotide. BioMS Medical Corp.
Lady

http://www.biomsmedical.com/ Got it.

[legzzalot]

See? This is why you guys rock!

[Gazelle]

I was first going to say that it sounded a lot like some people's sex lives, but that's really WAY COOL if it works and they get it approved!

I'd shoot up 2x a year. Keep us posted about it please!

[CayoKay]

hot off the wire, a Bloomberg Exclusive:

BioMS May Give Lilly $5 Billion Cure for Expiring Drug Patents

By Kelly Riddell

Dec. 26 (Bloomberg) -- BioMS Medical Corp., a one-drug biotechnology company in Edmonton, Alberta, may hold a partial answer as to how Eli Lilly & Co. will replace $9.9 billion in sales threatened by expiring patents.

Lilly signed a $497 million licensing and development agreement for BioMS’s dirucotide, potentially the first treatment for advanced forms of multiple sclerosis to come to market. The medicine, which entered final trials, has so far escaped side effects such as influenza-like symptoms, fatigue and skin cancer that were reported by Basel, Switzerland-based Novartis AG on fingolimod, another late-stage drug in testing for the disease.

A mid-level study of dirucotide, involving 218 subjects, had “very impressive features to it,” according to Bill Chin, Lily’s vice president of discovery and clinical investigation. The drug represents a chance for “a breakthrough,” he said.

http://www.bloomberg.com/apps/news?p...ZNs&refer=home

[jeep4wd]

New to this if interested please write me.In a 4 year study half way thru it.
Jim

[Dejibo]

I couldnt get the video to play, but read the article. sounds interesting.

[Desinie]

Jim,
Please tell us how you're doing on it. Thanks!